Supriya LifescienceQ3 FY24

Supriya Lifescience Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹620.65P/E: 28.1Market Cap: ₹5.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Supriya Lifescience aims to achieve INR 1,000 crores+ revenue by FY'27, driven by existing products, new product launches, and CDMO/CMO business.
  • Sustained year-on-year revenue growth of 20%-23% is targeted over the next three years.
  • Contribution from CMO/CDMO, especially the anaesthetic product (a $300 million global market), is expected to be significant and could exceed conservative projections.
  • Existing top products are growing at 5%-10%, with some products growing at around 8%-10%.
  • Addition of 4-5 new products annually via enhanced R&D.
  • Europe sales have increased substantially, indicating improved traction in regulated markets like Europe and North America.
  • Capacity expansion (including new module E with 350 KL added capacity) will double overall capacity, supporting volume growth.
  • New product categories include anaesthetics, anti-diabetic, and anti-anxiety therapies.

See what Supriya Lifescience management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
- The company plans capex of around INR100-120 crores for Module E at the Parshuram plant, mostly funded from IPO proceeds, indicating no immediate equity raise for this. - Additional capex of about INR60 crores is planned for Ambernath site expansion with environment clearance. - For the current fiscal year (FY24), capex is expected at around INR105-110 crores, and a similar amount is planned for FY25. - There is no explicit mention of any new fundraising through debt or equity in the near term. - The company appears to be funding expansions primarily through internal accruals and existing IPO proceeds. Summary: No new debt or equity fundraising is indicated currently; expansions are being funded largely through IPO proceeds and internal funds.

See what Supriya Lifescience management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Planned capex of around INR 105-120 crores in Q1 FY'25, mainly for Module E at the Lote Parshuram site.
  • Majority of this capex funded from IPO proceeds.
  • Module E is a new dedicated production block with ~350 KL capacity, expected operational by Q1 FY'25.
  • Ambernath greenfield site refurbished for bottling activities and API R&D; operational also by Q1 FY'25.
  • Additional INR 60 crores capex over the next two years planned for Ambernath site to support CDMO/CMO activities, especially anaesthetic product bottling.
  • Refurbishment planned for older modules (ABC) in the next fiscal.
  • Capex expansion is modular and phased, aligned with utilization and orders.
  • Asset turns target of 2.5x and above from this capex.
  • Expansion aims to support revenue growth to INR 1,000 crores by FY'27 and strengthen backward integration and new product launches.

Track Supriya Lifescience — get its next earnings analysis in your feed

How does Supriya Lifescience rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSupriya Lifescience
Rev 2Mar 3

How does Supriya Lifescience rank in Pharmaceuticals & Biotechnology?

Compare Supriya Lifescience against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →